Deep Vein Thrombosis Risk Factors

Patient‑Related Factors

• Advanced age (> 60 years) modestly raises the odds of deep vein thrombosis (OR 1.34) and accounts for approximately 3.6 % of the overall risk burden in the general population【@1】【@4】.
• Obesity (body‑mass index > 30 kg/m²) is an established independent risk factor for venous thromboembolism【@2】【@5】.
• A prior episode of deep vein thrombosis is the strongest individual predictor (OR 6.08), contributing about 22.7 % of the total risk【@1】【@4】.
• Documented inherited thrombophilia (deficiencies of protein C, protein S, or antithrombin) increases the odds of thrombosis (OR 5.88) and represents roughly 22.2 % of the overall risk【@1】【@4】.

Disease‑Related Factors

• Active malignancy elevates the risk of deep vein thrombosis 4‑ to 7‑fold (OR 2.65), responsible for roughly 12.3 % of the total risk【@1】【@4】【@5】.
• Certain cancer sites carry especially high thrombotic risk, notably pancreatic, brain, lung, ovarian, renal, and hematologic (especially lymphoma) malignancies【@7】【@5】.
• Presence of metastatic disease further amplifies thrombotic risk【@7】【@5】.
• Acute infections increase the odds of thrombosis (OR 1.48), contributing about 4.9 % of the overall risk【@1】【@4】.
• Critical illness is associated with odds ratios ranging from 1.65 to 2.10 and contributes 6.3‑13.7 % of the total risk, depending on whether deep vein thrombosis or bleeding is considered【@1】【@4】.
• Renal insufficiency is recognized as an established risk factor for venous thromboembolism【@2】.

Treatment‑Related Factors

• Prolonged immobility markedly raises the odds of thrombosis (OR 3.17) and accounts for 14.4 % of the overall risk【@1】【@4】.
• Hospital admission alone increases the annual incidence of deep vein thrombosis to approximately 239 cases per 100 000 hospitalized patients【@5】【@8】.
• Acute paralysis (e.g., spinal cord injury) elevates the odds (OR 2.97) and contributes 13.6 % of the total risk【@1】【@4】.
• Recent major surgery in patients with cancer roughly doubles the postoperative deep vein thrombosis risk and triples the risk of fatal pulmonary embolism【@7】.
• Traumatic injury, especially in individuals > 60 years, is a major predictor in validated post‑traumatic risk scores (e.g., Greenfield RAP, TESS)【@9】.
• Lower‑extremity fractures significantly increase thrombotic risk【@9】.
• Active chemotherapy regimens raise the odds of thrombosis about 6.5‑fold【@7】【@5】.
• Anti‑angiogenic agents (e.g., thalidomide, lenalidomide, bevacizumab) substantially increase thrombotic risk【@7】.
• Hormonal therapies, including tamoxifen and oral contraceptives, are associated with higher deep vein thrombosis incidence【@7】【@5】.
• Erythropoiesis‑stimulating agents have been linked to an elevated risk of venous thromboembolism【@7】【@5】.

Biological Markers

• Thrombocytosis (pre‑chemotherapy platelet count ≥ 350 × 10⁹/L) is associated with an increased risk of thrombosis【@7】【@5】.
• Leukocytosis is an established laboratory risk factor for deep vein thrombosis【@1】【@5】.
• Clinical signs such as tachycardia and fever correlate with higher thrombotic risk【@1】.
• Elevated C‑reactive protein is probably associated with deep vein thrombosis, supported by evidence of moderate certainty【@1】.
• High levels of D‑dimer and fibrinogen serve as biomarkers indicating heightened thrombotic risk【@1】.
• Peripheral leg edema is a clinical indicator linked to increased deep vein thrombosis risk【@1】.

Clinical Considerations

• Hospitalization alone contributes to more than 547 000 cases of deep vein thrombosis annually in the United States【@5】【@8】.
• The first three months following a cancer diagnosis represent the period of maximal thrombotic risk【@7】【@5】.

Risk Factors Contributing to Extensive Deep Vein Thrombosis

Patient‑Related Risk Factors

• Prior deep‑vein thrombosis increases the odds of a recurrent extensive DVT by approximately 6‑fold and accounts for about 23 % of the overall risk burden in the population 1.
• Age > 60 years modestly raises the risk (odds ratio ≈ 1.34) and contributes roughly 3.6 % of total risk 2.
• Body‑mass index > 30 kg/m² (obesity) is an independent risk factor for extensive DVT 2.
• Prolonged immobility (e.g., bed rest > 72 h) elevates the odds of extensive DVT by about 3.2‑fold, representing 14.4 % of overall risk 2.
• Acute paralysis (such as spinal‑cord injury) increases the odds by ≈ 2.97‑fold, accounting for 13.6 % of total risk 2.

Inherited Thrombophilia

• Presence of an inherited thrombophilic disorder raises the odds of extensive DVT by ≈ 5.9‑fold and explains roughly 22 % of the overall risk 1.
• Factor V Leiden mutation is the most common inherited variant, affecting ~5 % of individuals of Caucasian ancestry 1.
• Prothrombin G20210A mutation also confers increased thrombotic risk 1.
• Deficiencies of natural anticoagulants—antithrombin III, protein C, and protein S—each carry an odds ratio of about 11.1 for extensive DVT 3.
• Antiphospholipid syndrome is another inherited/acquired thrombophilia that markedly elevates DVT risk 3.
• Testing for thrombophilia is recommended primarily for young patients, unprovoked events, atypical clot locations, recurrent thrombosis, or a strong family history 1.

Malignancy‑Associated Risk (National Comprehensive Cancer Network)

• Active cancer increases the odds of extensive DVT by 2.6‑fold (overall risk contribution ≈ 12 %) and accounts for ~20 % of community VTE cases [4][5].
• Pancreatic cancer consistently shows the highest DVT risk among solid tumours, followed by brain tumours and other adenocarcinomas 5.
• Metastatic disease dramatically amplifies risk; distant metastases confer an odds ratio of ≈ 19.8 compared with localized disease [4][5].
• Hospitalized patients experience an incidence of 239 per 100 000 admissions, with an 8‑ to 22‑fold increase in VTE risk depending on surgical status 5.
• Central venous catheter placement in cancer patients is an additional recognized risk factor [4][5].

Immobility, Hospitalization, and Acute Medical Illness

• Critical illness requiring ICU/CCU care raises DVT risk 1.65‑ to 2.10‑fold, contributing 6‑14 % of total risk 2.
• Acute infections increase the odds of extensive DVT by ≈ 1.48‑fold (≈ 4.9 % of risk) and are associated with a three‑fold rise in VTE incidence within three months [4][2]5.
• Renal insufficiency is an established independent risk factor for extensive DVT 2.

Treatment‑Related Factors (National Comprehensive Cancer Network)

• Active chemotherapy elevates the odds of extensive DVT by roughly 6.5‑fold 5.
• Anti‑angiogenic agents (e.g., thalidomide, lenalidomide, bevacizumab) substantially increase DVT risk 6.
• Hormonal therapies—including tamoxifen, raloxifene, oral contraceptives, and hormone‑replacement therapy—are associated with higher DVT incidence 6.
• Erythropoiesis‑stimulating agents (ESAs) also contribute to increased thrombotic risk 6.

Laboratory and Clinical Markers

• Elevated D‑dimer and fibrinogen levels are biomarkers indicating heightened risk for extensive DVT 6.

Risk Factors and Epidemiology of Deep Vein Thrombosis

Patient‑Related Risk Factors

• The NCCN guidelines explain that DVT arises when slow venous flow, vessel injury, and a hyper‑coagulable state coexist, and most patients have several risk factors from different categories. 7, 8
• Advanced age (≥ 60 years) raises the risk of DVT by approximately 34 % and accounts for about 4 % of the overall risk burden. 8
• Obesity (body‑mass index > 30 kg/m²) independently increases DVT risk. 7, 8
• A history of prior DVT is the strongest personal predictor, conferring a 6‑fold increase in risk and representing roughly 23 % of total risk. 8
• Inherited thrombophilia (deficiencies of protein C, protein S, or antithrombin) elevates DVT risk nearly 6‑fold. 8
• Inherited thrombophilia contributes less to DVT risk in patients with active cancer. 7, 9
• Active infection increases DVT risk by 48 % and contributes about 5 % of the total risk. 8
• Heart failure, chronic kidney disease, and pregnancy are recognized as additional patient‑related risk factors. 10, 11 (heart failure), 8 (kidney disease), 7, 9 (pregnancy)

Disease‑Related Risk Factors

• Active malignancy raises DVT risk 4‑ to 7‑fold and accounts for roughly 20 % of community‑acquired DVT cases. 7, 8
• The highest‑risk solid tumours include pancreatic, brain, lung, ovarian, renal, gastric, bladder, and testicular cancers. 7
• Hematologic malignancies (lymphoma, acute leukaemia, multiple myeloma) are associated with particularly high DVT risk. 7
• Metastatic disease amplifies the risk dramatically—approximately 20‑fold higher than in patients with localized cancer. 7
• Admission to an intensive‑care unit increases DVT risk 1.7‑ to 2.1‑fold and contributes 6‑14 % of the overall risk. 8

Treatment‑Related Risk Factors

• Prolonged immobility or bed rest raises DVT risk > 3‑fold and accounts for about 14 % of total risk. 8
• Hospitalisation alone generates > 547 000 DVT events per year in the United States (≈ 239 cases per 100 000 hospitalised patients). 8, 9
• Acute paralysis from spinal‑cord injury increases DVT risk nearly 3‑fold. 8
• Anti‑angiogenic agents (e.g., thalidomide, lenalidomide, bevacizumab) substantially increase DVT incidence. 7
• Hormonal therapies—including tamoxifen, oral contraceptives, and hormone‑replacement therapy—elevate DVT rates. 7
• Erythropoiesis‑stimulating agents (ESAs) are linked to a higher thrombotic risk. 7
• Indwelling intravascular devices (central catheters, pacemakers, implantable defibrillators) confer the greatest risk for upper‑extremity DVT. 10, 11

Laboratory Warning Signs

• Elevated platelet count (thrombocytosis) before chemotherapy predicts an increased DVT risk. 7, 8
• Leukocytosis (high white‑blood‑cell count) is associated with higher DVT risk. 7, 8
• Anemia (hemoglobin < 10 g/dL) is a laboratory marker linked to greater DVT risk. 7, 8

Clinical Considerations

• DVT risk factors seldom occur in isolation; most patients have multiple contributing factors across the patient‑, disease‑, and treatment‑related categories. 7, 8
• In cancer patients, the combination of hospitalisation and active malignancy creates a particularly high thrombotic risk. 8, 9
• Recurrence of DVT is markedly higher in cancer patients (≈ 21 % vs 7 % at 12 months in non‑cancer patients). 7, 9
• Each additional risk factor compounds the overall thrombotic risk, emphasizing the need for comprehensive risk assessment. 7, 8

Protein C Deficiency Increases Deep Vein Thrombosis Risk

Inherited Thrombophilias

• Protein C deficiency is associated with an approximately 11‑fold higher odds of developing deep vein thrombosis compared with individuals without the deficiency 12